SE8701077L - Farmaceutisk beredning - Google Patents

Farmaceutisk beredning

Info

Publication number
SE8701077L
SE8701077L SE8701077A SE8701077A SE8701077L SE 8701077 L SE8701077 L SE 8701077L SE 8701077 A SE8701077 A SE 8701077A SE 8701077 A SE8701077 A SE 8701077A SE 8701077 L SE8701077 L SE 8701077L
Authority
SE
Sweden
Prior art keywords
hrs
exposure
releases
total
phosphate buffer
Prior art date
Application number
SE8701077A
Other languages
Unknown language ( )
English (en)
Other versions
SE460946B (sv
SE8701077D0 (sv
Inventor
C H Appelgren
E C Eskilsson
S I Johansson
Original Assignee
Lejus Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lejus Medical Ab filed Critical Lejus Medical Ab
Priority to SE8701077A priority Critical patent/SE460946B/sv
Publication of SE8701077D0 publication Critical patent/SE8701077D0/sv
Priority to EP88850087A priority patent/EP0287536A1/en
Priority to DK139388A priority patent/DK139388A/da
Priority to FI881238A priority patent/FI881238A/fi
Priority to NO881152A priority patent/NO881152L/no
Publication of SE8701077L publication Critical patent/SE8701077L/sv
Publication of SE460946B publication Critical patent/SE460946B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE8701077A 1987-03-16 1987-03-16 En multipel-unit-dos komposition av kinidinglukonat SE460946B (sv)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE8701077A SE460946B (sv) 1987-03-16 1987-03-16 En multipel-unit-dos komposition av kinidinglukonat
EP88850087A EP0287536A1 (en) 1987-03-16 1988-03-10 Pharmaceutical quinidine composition
DK139388A DK139388A (da) 1987-03-16 1988-03-15 Farmaceutisk praeparat
FI881238A FI881238A (fi) 1987-03-16 1988-03-15 Farmaceutisk beredning.
NO881152A NO881152L (no) 1987-03-16 1988-03-16 Farmasoeytisk blanding.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8701077A SE460946B (sv) 1987-03-16 1987-03-16 En multipel-unit-dos komposition av kinidinglukonat

Publications (3)

Publication Number Publication Date
SE8701077D0 SE8701077D0 (sv) 1987-03-16
SE8701077L true SE8701077L (sv) 1988-09-17
SE460946B SE460946B (sv) 1989-12-11

Family

ID=20367877

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8701077A SE460946B (sv) 1987-03-16 1987-03-16 En multipel-unit-dos komposition av kinidinglukonat

Country Status (5)

Country Link
EP (1) EP0287536A1 (sv)
DK (1) DK139388A (sv)
FI (1) FI881238A (sv)
NO (1) NO881152L (sv)
SE (1) SE460946B (sv)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
DE69020758T2 (de) * 1989-03-10 1995-12-07 Yamanouchi Pharma Co Ltd Die Wirkstoffabgabe steuerndes Überzugsmaterial für lang wirksame Formulierungen.
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
JPH07509702A (ja) * 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE10211289A1 (de) 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
WO1984000295A1 (en) * 1982-07-09 1984-02-02 Key Pharma Sustained release quinidine dosage form
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
JPH0759499B2 (ja) * 1984-02-10 1995-06-28 ベンツォン ファーマ エイ／エス 拡散被覆された複合単位服用剤

Also Published As

Publication number Publication date
DK139388A (da) 1988-12-08
SE460946B (sv) 1989-12-11
EP0287536A1 (en) 1988-10-19
FI881238A (fi) 1988-09-17
NO881152D0 (no) 1988-03-16
SE8701077D0 (sv) 1987-03-16
DK139388D0 (da) 1988-03-15
NO881152L (no) 1988-09-19
FI881238A0 (fi) 1988-03-15

Similar Documents

Publication Publication Date Title
PT85591A (en) Process for the preparation of multiple unit dosage pharmaceutical compositions comprising as a pharmaceutilly active compound l-dopa
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
BG60261B1 (bg) Лекарствена форма на цефаклор с продължително действие
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
ATE108650T1 (de) Methode und zusammensetzung zur oralen verabreichung von bioaktiven mitteln zur peyer's flecken.
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
DE69030387D1 (de) Chinoloncarbonsäure-metallionsäurekomplexe
SE8701077L (sv) Farmaceutisk beredning
SE8803583D0 (sv) Pharmaceutical composition
ATA379182A (de) Verfahren zur herstellung von presslingen mit retardierter wirkstofffreisetzung
UA40636C2 (uk) Фармацевтична композиція для одержання стабільного порошку, яка містить як активний компонент асоціацію ацетилсаліцилової кислоти та метоклопраміду, фармацевтичний препарат у формі порошку та спосіб одержання цього препарату
NO841372L (no) Fremgangsmaate for fremstilling av dipyridamol-preparater med ph-uavhengig regulert frigjoering
EG17992A (en) Preparation of a medicament for arthritis and theumatism
ATE45090T1 (de) Pharmazeutische zusammensetzung in oralen darreichungsformen.
WO1998057626A1 (en) Use of l-arginine or a pharmaceutically acceptable salt thereof for production of drugs for treatment of helicobacter pylori infections
KR880009652A (ko) 3-5-디클로로메토트랙세이트를 사용하는 류마티스성 관절염 치료법 및 그에 유용한 조성물
DE3265827D1 (en) Pharmaceutical composition of phosphonomicin in tablet form
ES2004693A6 (es) Un procedimiento para la preparacion de una composicion farmaceutica solida administrable por via oral, que contiene vinburnina como principio activo.
IT1238210B (it) Esteri del cefamandolo nafato, procedimento per la loro preparazione erelative composizioni farmaceutiche.
MX9708758A (es) Tratamiento de la enfermedad inflamatoria del intestino utilizando formas de dosis oral de acidos 3-omega-poliinsaturados.
RU94015877A (ru) Способ лечения вирусоносителей синдрома приобретенного иммунного дефицита

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8701077-3

Effective date: 19901001